Levothyroxine Sodium Tablets, 300 mcg recall — Accord Healthcare, Inc. (Class II)
Accord Healthcare, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Levothyroxine Sodium Tablets, 300 mcg — a Class II recall, initiated 2026-06-08 and posted to the FDA enforcement report on 2026-07-08, under recall number D-0656-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Subpotent Drug”. From the product description, the form is tablets, the strengths given are 300 mcg and 0.3mg, the package is described as 90 Tablets and it is marked Rx only. 1 National Drug Code number is printed in the record: 16729-458-15. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in NC, United States. It is the only recall number the FDA has filed under event ID 99194. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0656-2026 |
|---|---|
| FDA event ID | 99194 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Accord Healthcare, Inc. |
| Recall initiated | 2026-06-08 |
| Reported by FDA | 2026-07-08 |
| Report lag | 30 days from initiation to report |
| Distribution | US Nationwide. — Nationwide (US) |
| Firm location on record | NC, United States |
| Product description (source) | Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg), 90 Tablets bottles, Rx only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: lntas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-458-15. |
Reason reported by FDA
Subpotent Drug
2 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
8 identifying values matched by exact pattern in the 33-word product description above; each is a literal substring of it.
| Product named | Levothyroxine Sodium Tablets |
|---|---|
| Form | Tablets |
| Strength | 300 mcg · 0.3mg |
| Package | 90 Tablets |
| NDC | 16729-458-15 |
| Marketing category | Rx only |
| Manufactured by | lntas Pharmaceuticals Limited, Camp Road |
| Manufactured for | Accord Healthcare, Inc. |
Other indexed recalls of levothyroxine sodium
13 indexed records name levothyroxine sodium as the recalled substance. Matching is on the product-name prefix of the FDA's own text, so other strengths and packages are included.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Levothyroxine Sodium Tablets, 25 mcg | D-0700-2026 | Major Pharmaceuticals | 25 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 50 mcg | D-0701-2026 | Major Pharmaceuticals | 50 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0702-2026 | Major Pharmaceuticals | 75 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 88 mcg | D-0703-2026 | Major Pharmaceuticals | 88 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 112 mcg | D-0704-2026 | Major Pharmaceuticals | 112 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 125 mcg | D-0705-2026 | Major Pharmaceuticals | 125 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 150 mcg | D-0706-2026 | Major Pharmaceuticals | 150 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 25 mcg | D-0707-2026 | Major Pharmaceuticals | 25 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 50 mcg | D-0708-2026 | Major Pharmaceuticals | 50 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0709-2026 | Major Pharmaceuticals | 75 mcg · Tablets | 2026-07-29 |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| BD ChloraPrep Hi-Lite Orange, 2% | D-0643-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
| BD PurPrep, 8.3% | D-0644-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
| BD ChloraPrep Clear, 2% | D-0645-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
| ChloraPrep FREPP, 2% | D-0646-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
| BD ChloraPrep Hi-Lite Orange, 2% | D-0647-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
| BD ChloraPrep Hi-Lite Orange, 2% | D-0648-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
| BD ChloraPrep Scrub Teal, 2% | D-0649-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
| BD ChloraPrep Scrub Teal, 2% | D-0650-2026 | Carefusion 213, LLC | Class II | 2026-07-08 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 16729-458-15 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Accord Healthcare, Inc. (7 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0656-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0656-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-08
- Ingested
- 2026-08-22
- Record hash
ee6af5201510923e
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.